Revenue Breakdown
Composition ()
No data
Revenue Streams
Haleon PLC (HLN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oral health, accounting for 32.3% of total sales, equivalent to £848.00M. Other significant revenue streams include Pain relief and Respiratory health. Understanding this composition is critical for investors evaluating how HLN navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Haleon PLC maintains a gross margin of 64.19%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 21.87%, while the net margin is 15.23%. These profitability ratios, combined with a Return on Equity (ROE) of 10.23%, provide a clear picture of how effectively HLN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, HLN competes directly with industry leaders such as INSM and BIIB. With a market capitalization of $48.41B, it holds a leading position in the sector. When comparing efficiency, HLN's gross margin of 64.19% stands against INSM's 82.51% and BIIB's 72.46%. Such benchmarking helps identify whether Haleon PLC is trading at a premium or discount relative to its financial performance.
